Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 2, 1997, Pages 117-125

  Grem, Jean L ^a   Yee, Lorrin K ^a,b   Venzon, David J ^a   Takimoto, Chris H ^a   Allegra, Carmen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Circadian pharmacology; Dihydropyrimidine dehydrogenase; Fluorouracil

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICS; VARIANCE;

ADULT; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; INDIVIDUALITY; LEUKOCYTES, MONONUCLEAR; MALE; OXIDOREDUCTASES; PERIODICITY;

EID: 0031010583     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050635     Document Type: Article

References (34)

1. Grem JL (1996) 5-Fluoropyrimidines. In: Chabner BA, Longo DL, (eds) Cancer chemotherapy and biotherapy, principles and practice, 2nd edn. Lippincott-Raven, Philadelphia, pp 149-211
2. Seifert P, Baker L, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36: 123-128
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432
4. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-sarraf M (1985) A randomized trial of cisplatin plus 5-fluorouracil infusion and cisplatin plus 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56: 2740-2744
5. Hansen RM, Ryan L, Anderson T, et al (1996) A phase III trial of bolus 5-FU versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer J Natl Cancer Inst 88: 668-674
6. Weinerman B, Shah A, Fields A, et al (1992) Systemic infusion versus bolus therapy with 5 fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 15: 518-523
7. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 131: 1303-1311
8. Gardner MLG, Plumb JA (1981) Diurnal variation in the intestinal toxicity of 5-fluorouracil in the rat. Clin Sci 61: 717-722
9. 50 of 5-fluorouracil in mice. Pharmacology 28: 296-300
10. Peters GJ, van Dijk J, Nadal JC, et al (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1: 113-118
11. Roemeling R van, Hrushesky WJM (1990) Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst 82: 386-393
12. Minshull M, Gardner MLG (1984) The effects of time of administration of 5-fluorouracil on leucopenia in the rat. Eur J Cancer Clin Oncol 20: 857-858
13. Zhang R, Lu Z, Liu T, Soong S-J, Diasio RB (1993) Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: posible relevance to fluoropyrimidine therapy. Cancer Res 53: 2816-2822
14. Burns ER (1981) Circadian rhythmicity in DNA synthesis in untreated and saline-treated mice as a basis for improved chemotherapy. Cancer Res 41: 2795-2802
15. Harris BE, Song R, He YJ, et al (1988) Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Biochem Pharmacol 37: 4759-4762
16. Zhang R, Lu Z, Liu T, et al (1993) Circadian rhythm of rat spleen cytoplasmic thymidine kinase. Biochem Pharmacol 45: 1115-1119
17. Smaaland R, Laerum OD, Lote K, et al (1991) DNA synthesis in human bone marrow is circadian stage dependent. Blood 77: 2603-2611
18. Buchi KN, Moore JG, Hrushesky WJM, et al (1991) Circadian rhythm of cellular proliferation in human rectal mucosa. Gastroenterology 101: 410-415
19. Petit E, Milano G, Levi F, et al (1988) Circadian rhythm-varying plasma concentration of 5-fluorouracil during a fiveday continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1676-1679
20. Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
21. Fleming RF, Milano G, Thyss A, et al (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902
22. Lu A, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438
23. Yee LK, Allegra CJ, Steinberg SM, et al (1992) Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during therapy with 5-fluorouracil, leucovorin, and interferon α-2a. J Natl Cancer Inst 84: 1820-1825
24. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest [Suppl] 21: 77-81
25. Marsh JC and Perry S (1964) The reduction of thymine by human leukocytes. Arch Biochem Biophys 104: 146-149
26. Sommadossi JP, Gewirtz DA, Diasio RB, et al (1982) Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 257: 8171-8176
27. Tong YL (1976) Parameter estimation in studying circadian rythms. Biometrics 32:85-94
28. Roemeling R von, Hrushesky WJM (1989) Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 7: 1710-1719
29. Hrushesky WJM, von Roemeling R, Lanning TM, Rabatin JT (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8: 1504-1513
30. Wesen C, Hrushesky WJM, Roemeling R von (1992) Circadian modification of intra-arterial 5-fluoro-2′-deoxyuridine infusion rate reduces its toxicity and permits higher dose-intensity. J Infus Chemother 2: 69-75
31. Levi F, Misset JL, Breinza S, et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893-900
32. Levi FA, Zidani R, Vannetzel J-M, et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86: 1608-1617
33. Bjarnason GA, Kerr IG, Doyle N, Macdonald M, Stone M (1993) Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother Pharmacol 33: 221-228
34. Fleming GF, Schilsky RL, Mick R, O'Brien SM, Vogelzang NJ, Ratain MJ (1994) Circadian variation of 5-fluorouracil plasma levels during continuous infusion 5-FU and leucovorin in patients with hepatic or renal dysfunction (abstract). Ann Oncol 5 [Suppl. 5]: 236